Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Staar Surgical TICL

This article was originally published in The Gray Sheet

Executive Summary

Receipt of CE mark for toric implantable contact lens EU sales makes Staar's TICL the first posterior phakic intraocular lens able to reduce pre-existing astigmatism alongside myopia or hyperopia correction, the company says Dec. 3. The Monrovia, Calif. firm gained conditional IDE clearance in January for a 125-patient U.S. trial investigating the TICL to treat myopia of -3.0 to 20 diopters - and astigmatism of 1.0 to 4.0 D (1"The Gray Sheet" Jan. 14, 2002, In Brief). Staar implanted the first device in a U.S. patient's eye in August, with "excellent results [and] no surprises"...

You may also be interested in...

Staar Surgical TICL

Toric implantable contact lens gains conditional investigational device exemption clearance for a 125-patient U.S. trial to treat myopia of -3.0 to -20 diopters and astigmatism of 1.0 to 4.0 diopters. The device "is the only phakic intraocular lens" for pre-existing astigmatism and myopia, Staar says. An ongoing U.S. study of a non-toric myopia version, including 529 enrolled cases, shows a 2.3% incidence of lens opacities, with eight of the 12 opacities being "non progressive and showing no loss of best-corrected visual acuity," Staar notes...

Health And Wellness Trademark Review 14 January, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Claim That Supplement Boosts Children’s Focus Could Spur FTC Attention

Creekside Natural Therapeutics might hear from the FTC after failing to show in an industry self-regulation forum that it would correct misleading claims for its Focused Mind Jr. supplement promoted as an alternative to ADHD drugs.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts